Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 16/20 | 0.89 |
| ▸ | DRD2 | P14416 | 15/20 | 0.89 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420435 | 0.94 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14502886 | 0.94 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL6846737 | 0.94 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14502887 | 0.89 | DRD4 (0.89) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14533029 | 0.89 | DRD4 (0.89) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL5414732 | 0.85 | DRD4 (0.71) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14502885 | 0.85 | DRD4 (0.71) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL5418956 | 0.84 | DRD4 (0.80) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL6844226 | 0.81 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL7098507 | 0.81 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220753-B2 | 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | PFIZER INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040214830-A1 | 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | DESAI KISHOR A | 2004-10-28 | — | — | US | disclosed |
| US-20030055061-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-20020132811-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | DESAI KISHOR A (US) | 2002-09-19 | — | — | US | disclosed |
| EP-0783503-B1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[ 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6231833-B1 | ADMINISTERING TO THE MAMMAL FOR TREATING SEROTONIN SYSTEM RELATED DISORDERS AN EFFECTIVE AMOUNT OF 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-A)PYRAZINE DERIVATIVE AS LIGANDS FOR SEROTONIN RECEPTOR | PFIZER INC | 2001-05-15 | — | — | US | disclosed |
| EP-1074257-A1 | 2,7-Substituted octahydro-1H-pyrido (1,2-A)pyrazine derivatives as ligands for serotonin receptors | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-5852031-A | 2,7-substituted octahydro-1H-pyrido 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0783503-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO 1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010571-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132811-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | DRD4 65/4885DRD2 27/4885HTR1A 2/4885 |
| US-20040214830-A1 | 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | DRD4 65/4885DRD2 27/4885HTR1A 2/4885 |
| US-20030055061-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | DRD4 65/4885DRD2 27/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.